Alnylam

Alnylam and Regeneron report updated positive Phase I results of Alzheimer’s drug
Clinical Trials Arena
Mon, 07/17/23 - 08:41 am
Alnylam
clinical trials
ALN-APP
Alzheimer's disease
5 FDA decisions to watch in the third quarter
BioPharma Dive
Mon, 06/26/23 - 10:04 am
FDA
SAGE Therapeutics
Biogen
zuranolone
Eisai
Leqembi
Sanofi
AstraZeneca
nirsevimab
Iveric Bio
Zimura
Alnylam
Onpattro
Moderna hits back at Alnylam's 'baseless' patent infringement claims
Fierce Pharma
Tue, 05/16/23 - 10:38 pm
Moderna Therapeutics
Alnylam
MRNA
vaccines
legals
Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle
BioPharma Dive
Fri, 04/28/23 - 10:08 am
Alnylam
Regeneron
clinical trials
Alzheimer's disease
ALN-APP
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Fierce Biotech
Mon, 04/24/23 - 10:26 am
Ionis Pharmaceuticals
AstraZeneca
eplontersen
Alnylam
ATTR
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
Fierce Biotech
Mon, 03/27/23 - 10:22 am
AstraZeneca
Ionis Pharmaceuticals
aplontersen
Alnylam
Onpattro
clinical trials
ATTRv-PN
JPM Day 1: Highlights
BioSpace
Mon, 01/9/23 - 11:01 pm
JPMHC 2023
Sarepta Therapeutics
Biomarin
Alnylam
JNJ
Arrowhead Pharmaceuticals
Novartis
Bristol Myers Squibb
10 clinical trials to watch in the first half of 2023
BioPharma Dive
Tue, 01/3/23 - 10:57 am
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Insmed, Alnylam and others make Science's list of top 20 biopharma employers
Endpoints
Sun, 11/6/22 - 01:32 pm
employers
Inbsmed
Alnylam
Regeneron
Incyte
Sanofi, Alnylam Q3 Reports Hint at Early Pipeline Impacts from IRA
BioSpace
Mon, 10/31/22 - 04:17 pm
Sanofi
Alnylam
earnings
Inflation Reduction Act
legislation
drug pricing
Alnylam scraps trial in rare eye disorder, blaming drug price reforms
Pharmaphorum
Fri, 10/28/22 - 10:25 am
Alnylam
RNAi
vutrisiran
Stargardt disease
Inflation Reduction Act
drug pricing
The gloom deepens for biopharma stocks
EP Vantage
Mon, 10/10/22 - 06:54 pm
biopharma stocks
AbbVie
Alnylam
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eisai
Eli Lilly
GSK
Intellia Therapeutics
Regeneron
Roche
Sanofi
Sarepta Therapeutics
FDA Review: Alnylam, Cytokinetics, Eli Lilly and More
BioSpace
Sun, 10/9/22 - 06:06 pm
FDA
Alnylam
Cytokinetics
Eli Lilly
Owlet
Boston Cell Standards
Kiromic Biopharma
Entera Bio
Transcenta Holdings
Kira Pharmaceuticals
Kite Pharma
Poxel
Seneca Therapeutics
FDA approves label expansion of Alnylam’s Oxlumo for PH1
Pharmaceutical Business Review
Fri, 10/7/22 - 10:38 am
Alnylam
FDAA
Oxlumo
advanced primary hyperoxaluria
PH1
Alnylam's new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst
Fierce Pharma
Mon, 10/3/22 - 11:41 pm
Alnylam
Onpattro
Pfizer
ATTR-CM
Alnylam details anticipated results from heart disease drug trial
BioPharma Dive
Thu, 09/8/22 - 10:47 am
Alnylam
clinical trials
Onpattro
transthyretin amyloidosis with cardiomyopathy
Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease
Fierce Biotech
Wed, 09/7/22 - 10:18 am
AstraZeneca
Ionis Pharmaceuticals
Alnylam
antisense
ATTRv-PN
aplontersen
Alnylam clears phase 2 test for Regeneron-partnered nephropathy med, as it looks to play catch-up against Calliditas
Fierce Biotech
Tue, 08/30/22 - 11:48 am
Alnylam
Regeneron
Calliditas
immunoglobin A nephropathy
clinical trials
Alnylam drug succeeds in heart study, setting stage for FDA filing and showdown with Pfizer
MedCity News
Thu, 08/4/22 - 11:09 am
Alnylam
Pfizer
Onpattro
hATTR
Alnylam reveals longer wait for anticipated drug trial results
BioPharma Dive
Thu, 07/28/22 - 12:25 pm
Alnylam
earnings
clinical trials
Onpattro

Pages